risperidone has been researched along with Metabolic Syndrome in 45 studies
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.
Metabolic Syndrome: A cluster of symptoms that are risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components of metabolic syndrome include ABDOMINAL OBESITY; atherogenic DYSLIPIDEMIA; HYPERTENSION; HYPERGLYCEMIA; INSULIN RESISTANCE; a proinflammatory state; and a prothrombotic (THROMBOSIS) state.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We examine weight gain and metabolic consequences of risperidone monotherapy in children with autism spectrum disorder (ASD)." | 9.22 | Weight Gain and Metabolic Consequences of Risperidone in Young Children With Autism Spectrum Disorder. ( Aman, MG; Arnold, LE; Boorin, SJ; Caprio, S; Challa, SA; Deng, Y; Dziura, J; Jeon, S; McCracken, JT; McDougle, CJ; Nicol, G; Scahill, L; Vitiello, B, 2016) |
| "Changes in FRS and metabolic syndrome status were compared between patients with BMI ≥ 27 and non-HDL-C ≥ 130 mg/dL randomly assigned to stay on stable current treatment (olanzapine, quetiapine, or risperidone) or switch to treatment with aripiprazole with 24 weeks of follow-up." | 9.17 | Effects of switching from olanzapine, quetiapine, and risperidone to aripiprazole on 10-year coronary heart disease risk and metabolic syndrome status: results from a randomized controlled trial. ( Byerly, MJ; Glick, ID; Hamer, RM; Khan, AY; Lamberti, JS; McEvoy, JP; Nasrallah, HA; Ray, N; Steinbook, RM; Stroup, TS, 2013) |
| "The aim of this article was to examine the effects of switching from the antipsychotic olanzapine to risperidone on the prevalence of the metabolic syndrome in high-risk overweight or obese patients with schizophrenia or schizoaffective disorder." | 9.11 | Effects of switching from olanzapine to risperidone on the prevalence of the metabolic syndrome in overweight or obese patients with schizophrenia or schizoaffective disorder: analysis of a multicenter, rater-blinded, open-label study. ( Bossie, CA; Greenspan, A; Meyer, JM; Pandina, G; Turkoz, I, 2005) |
| "To conduct meta-analyses of all published association studies on the HTR2C -759C/T (rs3813829) polymorphism and olanzapine-induced weight gain in schizophrenia patients and on the HTR2C -759C/T, -697G/C (rs518147) and rs1414334:C> G polymorphisms and olanzapine/clozapine/risperidone-induced metabolic syndrome in schizophrenia patients." | 8.90 | HTR2C polymorphisms, olanzapine-induced weight gain and antipsychotic-induced metabolic syndrome in schizophrenia patients: a meta-analysis. ( Gui, X; Hu, G; Ma, X; Maimaitirexiati, T; Xu, G; Zhang, R; Zhang, W, 2014) |
| "Atypical antipsychotics such as risperidone cause drug-induced metabolic syndrome." | 8.02 | The atypical antipsychotic risperidone targets hypothalamic melanocortin 4 receptors to cause weight gain. ( Arnold, AG; Birnbaum, SG; Chen, X; Jia, L; Li, L; Li, X; Liu, C; Sohn, JW; Wan, R; Wyler, SC; Yoo, ES, 2021) |
| " We reviewed the electronic medical records of patients with schizophrenia who received aripiprazole, olanzapine or risperidone monotherapies for at least three months." | 7.77 | The prevalence of metabolic syndrome in Korean patients with schizophrenia receiving a monotherapy with aripiprazole, olanzapine or risperidone. ( Ahn, YM; Jung, DC; Kang, UG; Kim, EY; Kim, SH; Kim, YS; Lee, NY; Sung, KH; Yu, HY, 2011) |
| "Despite the limited number of children included, our results confirm a strong link between prescription of risperidone in EOS and risk of obesity." | 7.76 | [Metabolic side effects of risperidone in early onset schizophrenia]. ( Bordet, R; Delion, P; Duhamel, A; Goeb, JL; Jardri, R; Kechid, G; Marco, S; Thomas, P, 2010) |
| "The long-term use of risperidone, especially when weight is above normal, is associated with a number of metabolic abnormalities but a low prevalence of the metabolic syndrome phenotype." | 7.75 | Weight gain and metabolic abnormalities during extended risperidone treatment in children and adolescents. ( Acion, L; Calarge, CA; Kuperman, S; Schlechte, JA; Tansey, M, 2009) |
| "Data were collected from medical records from January 1992 to December 2003 and included age, gender, race, diagnosis, family history of diabetes, and age at clozapine initiation for clozapine-treated patients with schizophrenia or schizoaffective disorder (DSM-IV criteria)." | 7.73 | Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study. ( Borba, CP; Cather, C; Copeland, PM; Evins, AE; Freudenreich, O; Goff, DC; Hayden, DL; Henderson, DC; Louie, PM; Nguyen, DD, 2005) |
| "With the second-generation antipsychotics (SGAs) widely applied to treat patients with schizophrenia, adverse effects, especially the metabolic syndrome (MetS), were paid more attention following by the efficacy of SGAs." | 6.90 | Efficacy and safety of electroacupuncture on metabolic syndrome due to olanzapine and risperidone: Study protocol for a randomized controlled pilot trial. ( Chen, P; Jia, H; Ning, Y; Yin, D; Zhu, H, 2019) |
| "We examine weight gain and metabolic consequences of risperidone monotherapy in children with autism spectrum disorder (ASD)." | 5.22 | Weight Gain and Metabolic Consequences of Risperidone in Young Children With Autism Spectrum Disorder. ( Aman, MG; Arnold, LE; Boorin, SJ; Caprio, S; Challa, SA; Deng, Y; Dziura, J; Jeon, S; McCracken, JT; McDougle, CJ; Nicol, G; Scahill, L; Vitiello, B, 2016) |
| "Changes in FRS and metabolic syndrome status were compared between patients with BMI ≥ 27 and non-HDL-C ≥ 130 mg/dL randomly assigned to stay on stable current treatment (olanzapine, quetiapine, or risperidone) or switch to treatment with aripiprazole with 24 weeks of follow-up." | 5.17 | Effects of switching from olanzapine, quetiapine, and risperidone to aripiprazole on 10-year coronary heart disease risk and metabolic syndrome status: results from a randomized controlled trial. ( Byerly, MJ; Glick, ID; Hamer, RM; Khan, AY; Lamberti, JS; McEvoy, JP; Nasrallah, HA; Ray, N; Steinbook, RM; Stroup, TS, 2013) |
| "To compare longer-term safety and effectiveness of the 4 most commonly used atypical antipsychotics (aripiprazole, olanzapine, quetiapine, and risperidone) in 332 patients, aged > 40 years, having psychosis associated with schizophrenia, mood disorders, posttraumatic stress disorder, or dementia, diagnosed using DSM-IV-TR criteria." | 5.17 | Comparison of longer-term safety and effectiveness of 4 atypical antipsychotics in patients over age 40: a trial using equipoise-stratified randomization. ( Arndt, S; Glorioso, DK; Golshan, S; Henry, R; Jeste, DV; Jin, H; Kraemer, HC; Mudaliar, S; Shih, PA, 2013) |
| "The present study aimed to investigate the effects of clozapine, olanzapine, risperidone, and sulpiride on glucose and lipid metabolism in first-episode schizophrenia." | 5.12 | Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia. ( Guo, WB; Guo, XF; Liu, ZN; Tang, JS; Wu, RR; Zhai, JG; Zhao, JP, 2006) |
| "The aim of this article was to examine the effects of switching from the antipsychotic olanzapine to risperidone on the prevalence of the metabolic syndrome in high-risk overweight or obese patients with schizophrenia or schizoaffective disorder." | 5.11 | Effects of switching from olanzapine to risperidone on the prevalence of the metabolic syndrome in overweight or obese patients with schizophrenia or schizoaffective disorder: analysis of a multicenter, rater-blinded, open-label study. ( Bossie, CA; Greenspan, A; Meyer, JM; Pandina, G; Turkoz, I, 2005) |
| "To conduct meta-analyses of all published association studies on the HTR2C -759C/T (rs3813829) polymorphism and olanzapine-induced weight gain in schizophrenia patients and on the HTR2C -759C/T, -697G/C (rs518147) and rs1414334:C> G polymorphisms and olanzapine/clozapine/risperidone-induced metabolic syndrome in schizophrenia patients." | 4.90 | HTR2C polymorphisms, olanzapine-induced weight gain and antipsychotic-induced metabolic syndrome in schizophrenia patients: a meta-analysis. ( Gui, X; Hu, G; Ma, X; Maimaitirexiati, T; Xu, G; Zhang, R; Zhang, W, 2014) |
| " (2) Articles published between 2004 and 2008 were identified by a PubMed search with the keywords weight gain, metabolic, glucose, insulin, and lipid AND dose combined with amisulpride, aripiprazole, clozapine, quetiapine, risperidone, sertindole, and ziprasidone." | 4.85 | Are weight gain and metabolic side effects of atypical antipsychotics dose dependent? A literature review. ( De Hert, M; Simon, V; van Winkel, R, 2009) |
| "Atypical antipsychotics such as risperidone cause drug-induced metabolic syndrome." | 4.02 | The atypical antipsychotic risperidone targets hypothalamic melanocortin 4 receptors to cause weight gain. ( Arnold, AG; Birnbaum, SG; Chen, X; Jia, L; Li, L; Li, X; Liu, C; Sohn, JW; Wan, R; Wyler, SC; Yoo, ES, 2021) |
| "Eleven single nucleotide polymorphisms (SNPs) of SREBF1 and five of SCAP were genotyped in a Han Chinese population in Beijing, China: a sample of 722 schizophrenia patients on monotherapy with AAPs (clozapine, olanzapine or risperidone)." | 3.83 | Association between SCAP and SREBF1 gene polymorphisms and metabolic syndrome in schizophrenia patients treated with atypical antipsychotics. ( Chen, J; Li, Y; Liang, S; Shi, S; Shi, Y; Wang, Y; Xu, Y; Yang, L, 2016) |
| "Children treated with risperidone or quetiapine are at a significant risk for developing obesity, elevated waist circumference, and dyslipidemia during 12 months of treatment." | 3.81 | Increased Risk of Obesity and Metabolic Dysregulation Following 12 Months of Second-Generation Antipsychotic Treatment in Children: A Prospective Cohort Study. ( Davidson, J; Nguyen, D; Panagiotopoulos, C; Ronsley, R, 2015) |
| "Following several years of treatment, risperidone discontinuation is associated with a reversal of the excessive weight gain, mediated by a negative energy balance, and a corresponding improvement in cardiometabolic parameters." | 3.80 | Cardiometabolic outcomes in children and adolescents following discontinuation of long-term risperidone treatment. ( Burns, TL; Calarge, CA; Nicol, G; Schlechte, JA, 2014) |
| "We recruited 39 first-episode schizophrenia (FES) patients and determined serum profile of total homocysteine (tHcy), folate, vitamin B12, lipoproteins and glucose at baseline and after 12 weeks of treatment with second-generation antipsychotics (SGA) including olanzapine and risperidone in monotherapy." | 3.80 | Effects of second-generation antipsychotics on selected markers of one-carbon metabolism and metabolic syndrome components in first-episode schizophrenia patients. ( Frydecka, D; Kiejna, A; Misiak, B; Ślęzak, R; Łaczmański, Ł, 2014) |
| " The study included 456 schizophrenia patients treated with clozapine (n=171), olanzapine (n=91) and risperidone (n=194), for an average of 45." | 3.78 | Gene-gene interactions of the INSIG1 and INSIG2 in metabolic syndrome in schizophrenic patients treated with atypical antipsychotics. ( Bai, YM; Chen, JY; Chen, TT; Hong, CJ; Lin, E; Liou, YJ; Tsai, SJ, 2012) |
| "Compared with weight measured concurrently, the rate of weight gain in risperidone-treated children accounts for an equal or larger share of the variance in certain cardiometabolic outcomes (eg, HDL cholesterol [ΔR(2) = 8% vs ΔR(2) = 11%] and high-sensitivity C-reactive protein [ΔR(2) = 5% vs ΔR(2) = 9%]) and may serve as a treatment target." | 3.78 | Rate of weight gain and cardiometabolic abnormalities in children and adolescents. ( Burns, TL; Calarge, CA; Fiedorowicz, JG; Haynes, WG; Xie, D, 2012) |
| " We reviewed the electronic medical records of patients with schizophrenia who received aripiprazole, olanzapine or risperidone monotherapies for at least three months." | 3.77 | The prevalence of metabolic syndrome in Korean patients with schizophrenia receiving a monotherapy with aripiprazole, olanzapine or risperidone. ( Ahn, YM; Jung, DC; Kang, UG; Kim, EY; Kim, SH; Kim, YS; Lee, NY; Sung, KH; Yu, HY, 2011) |
| " The levels of metabolic syndrome-related biomarkers including serum adiponectin, leptin, and ghrelin were measured with an enzyme-linked immunosorbent assay." | 3.77 | Association of serum levels of leptin, ghrelin, and adiponectin in schizophrenic patients and healthy controls. ( Chang, CM; Chang, PY; Huang, TL; Liu, CY; Tsai, MC, 2011) |
| "Despite the limited number of children included, our results confirm a strong link between prescription of risperidone in EOS and risk of obesity." | 3.76 | [Metabolic side effects of risperidone in early onset schizophrenia]. ( Bordet, R; Delion, P; Duhamel, A; Goeb, JL; Jardri, R; Kechid, G; Marco, S; Thomas, P, 2010) |
| "The long-term use of risperidone, especially when weight is above normal, is associated with a number of metabolic abnormalities but a low prevalence of the metabolic syndrome phenotype." | 3.75 | Weight gain and metabolic abnormalities during extended risperidone treatment in children and adolescents. ( Acion, L; Calarge, CA; Kuperman, S; Schlechte, JA; Tansey, M, 2009) |
| " Thirty-six nonobese subjects with schizophrenia or schizoaffective disorder, matched by body mass index and treated with either clozapine, olanzapine, or risperidone, were included in the analysis." | 3.73 | Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. ( Allison, DB; Anderson, EJ; Borba, CP; Cagliero, E; Copeland, PM; Daley, TB; Evins, AE; Goff, DC; Hayden, D; Henderson, DC; Schoenfeld, D; Weber, MT, 2005) |
| "Data were collected from medical records from January 1992 to December 2003 and included age, gender, race, diagnosis, family history of diabetes, and age at clozapine initiation for clozapine-treated patients with schizophrenia or schizoaffective disorder (DSM-IV criteria)." | 3.73 | Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study. ( Borba, CP; Cather, C; Copeland, PM; Evins, AE; Freudenreich, O; Goff, DC; Hayden, DL; Henderson, DC; Louie, PM; Nguyen, DD, 2005) |
| "Atypical antipsychotics, especially clozapine and olanzapine, have been increasingly associated with weight gain and other adverse metabolic events (diabetes mellitus, hyperlipidemia) in non-mentally retarded populations." | 3.73 | Metabolic effects associated with atypical antipsychotic treatment in the developmentally disabled. ( Ball, MP; Bodfish, JW; Heeth, WL; Mahorney, SL; McKee, JR, 2005) |
| " Role of ghrelin (RIA), resistin and TNF-alpha (ELISA) in weight gain and insulin resistance (fasting plasma insulin, HOMA, ELISA) was studied in Hungarian psychiatryic patients (n=60) treated with SGA (clozapine, olanzapine, risperidone, quetiapine, 15 each)." | 3.73 | [Possible connection between ghrelin, resistin and TNF-alpha levels and the metabolic syndrome caused by atypical antipsychotics]. ( Birkás Kováts, D; Cseh, K; Faludi, G; Palik, E, 2005) |
| "With the second-generation antipsychotics (SGAs) widely applied to treat patients with schizophrenia, adverse effects, especially the metabolic syndrome (MetS), were paid more attention following by the efficacy of SGAs." | 2.90 | Efficacy and safety of electroacupuncture on metabolic syndrome due to olanzapine and risperidone: Study protocol for a randomized controlled pilot trial. ( Chen, P; Jia, H; Ning, Y; Yin, D; Zhu, H, 2019) |
| "Olanzapine has a higher propensity to cause derangement of some parameters of lipid profile than risperidone." | 2.77 | Comparison of fasting blood sugar and serum lipid profile changes after treatment with atypical antipsychotics olanzapine and risperidone. ( Bhutani, G; Gupta, R; Kaushal, J, 2012) |
| "Aripiprazole has the most consistent evidence of symptom improvement; however, this improvement is small." | 2.53 | Behavioral Disorders in Dementia: Appropriate Nondrug Interventions and Antipsychotic Use. ( Cocker, KE; Reese, TR; Thiel, DJ, 2016) |
| "Risperidone was the most commonly prescribed SGA (n = 99; 41%; average daily dose 1." | 1.46 | Second-Generation Antipsychotic Utilization and Metabolic Parameter Monitoring in an Inpatient Pediatric Population: A Retrospective Analysis. ( Fabian, TJ; Kibler, AV; Nolt, VD; Wilkening, GL, 2017) |
| " One-third of children and adolescents had abnormal serum triglycerides and cholesterol; however, a dose-response was not demonstrated." | 1.40 | Metabolic changes in first-episode early-onset schizophrenia with second-generation antipsychotics. ( Amminger, GP; Becker, J; O'Donoghue, B; Papageorgiou, K; Schäfer, MR, 2014) |
| "Olanzapine-treated patients had significantly higher plasma triglyceride concentrations (2." | 1.32 | Development of an atherogenic metabolic risk factor profile associated with the use of atypical antipsychotics. ( Alméras, N; Bouchard, RH; Cadrin, C; Demers, MF; Després, JP; Mottard, JP; Roy, MA; Villeneuve, J, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 18 (40.00) | 29.6817 |
| 2010's | 24 (53.33) | 24.3611 |
| 2020's | 3 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Ning, Y | 1 |
| Jia, H | 1 |
| Chen, P | 1 |
| Zhu, H | 1 |
| Yin, D | 1 |
| Zhang, Y | 1 |
| Wang, Q | 1 |
| Reynolds, GP | 1 |
| Yue, W | 1 |
| Deng, W | 1 |
| Yan, H | 1 |
| Tan, L | 1 |
| Wang, C | 1 |
| Yang, G | 1 |
| Lu, T | 1 |
| Wang, L | 1 |
| Zhang, F | 1 |
| Yang, J | 1 |
| Li, K | 1 |
| Lv, L | 1 |
| Tan, Q | 1 |
| Li, Y | 2 |
| Yu, H | 1 |
| Zhang, H | 1 |
| Ma, X | 3 |
| Yang, F | 1 |
| Li, L | 2 |
| Chen, Q | 1 |
| Wei, W | 1 |
| Zhao, L | 1 |
| Wang, H | 1 |
| Li, X | 2 |
| Guo, W | 1 |
| Hu, X | 1 |
| Tian, Y | 1 |
| Ren, H | 1 |
| Coid, J | 1 |
| Zhang, D | 1 |
| Li, T | 1 |
| Mattingly, GW | 1 |
| Haddad, PM | 1 |
| Tocco, M | 1 |
| Xu, J | 1 |
| Phillips, D | 1 |
| Pikalov, A | 1 |
| Loebel, A | 1 |
| Yoo, ES | 1 |
| Wyler, SC | 1 |
| Chen, X | 1 |
| Wan, R | 1 |
| Arnold, AG | 1 |
| Birnbaum, SG | 1 |
| Jia, L | 1 |
| Sohn, JW | 1 |
| Liu, C | 1 |
| Stroup, TS | 1 |
| Byerly, MJ | 1 |
| Nasrallah, HA | 1 |
| Ray, N | 1 |
| Khan, AY | 1 |
| Lamberti, JS | 1 |
| Glick, ID | 1 |
| Steinbook, RM | 1 |
| McEvoy, JP | 1 |
| Hamer, RM | 1 |
| O'Donoghue, B | 1 |
| Schäfer, MR | 1 |
| Becker, J | 1 |
| Papageorgiou, K | 1 |
| Amminger, GP | 1 |
| Jiang, P | 1 |
| Zhu, MQ | 1 |
| Li, HD | 1 |
| Liu, YP | 1 |
| Cai, HL | 1 |
| Zhang, LM | 1 |
| Calarge, CA | 3 |
| Nicol, G | 2 |
| Schlechte, JA | 2 |
| Burns, TL | 2 |
| Maimaitirexiati, T | 1 |
| Zhang, R | 1 |
| Gui, X | 1 |
| Zhang, W | 1 |
| Xu, G | 1 |
| Hu, G | 1 |
| Misiak, B | 1 |
| Frydecka, D | 1 |
| Łaczmański, Ł | 1 |
| Ślęzak, R | 1 |
| Kiejna, A | 1 |
| Ronsley, R | 1 |
| Nguyen, D | 1 |
| Davidson, J | 2 |
| Panagiotopoulos, C | 2 |
| Yang, L | 1 |
| Chen, J | 1 |
| Wang, Y | 1 |
| Liang, S | 1 |
| Shi, Y | 1 |
| Shi, S | 1 |
| Xu, Y | 1 |
| Scahill, L | 1 |
| Jeon, S | 1 |
| Boorin, SJ | 1 |
| McDougle, CJ | 1 |
| Aman, MG | 1 |
| Dziura, J | 1 |
| McCracken, JT | 1 |
| Caprio, S | 1 |
| Arnold, LE | 1 |
| Deng, Y | 1 |
| Challa, SA | 1 |
| Vitiello, B | 1 |
| Mennella, C | 1 |
| Dickstein, DP | 1 |
| Reese, TR | 1 |
| Thiel, DJ | 1 |
| Cocker, KE | 1 |
| Nolt, VD | 1 |
| Kibler, AV | 1 |
| Wilkening, GL | 1 |
| Fabian, TJ | 1 |
| Lee, E | 1 |
| Leung, CM | 1 |
| Mulder, H | 1 |
| Cohen, D | 1 |
| Scheffer, H | 1 |
| Gispen-de Wied, C | 1 |
| Arends, J | 1 |
| Wilmink, FW | 1 |
| Franke, B | 1 |
| Egberts, AC | 1 |
| Acion, L | 1 |
| Kuperman, S | 1 |
| Tansey, M | 1 |
| Khan, RA | 1 |
| Mican, LM | 1 |
| Suehs, BT | 1 |
| Simon, V | 1 |
| van Winkel, R | 1 |
| De Hert, M | 2 |
| Weiss, M | 1 |
| Giles, L | 1 |
| Gibbins, C | 1 |
| Kuzeljevic, B | 1 |
| Harrison, R | 1 |
| Gross, C | 1 |
| Blasey, CM | 1 |
| Roe, RL | 1 |
| Belanoff, JK | 1 |
| Goeb, JL | 1 |
| Marco, S | 1 |
| Duhamel, A | 1 |
| Kechid, G | 1 |
| Bordet, R | 1 |
| Thomas, P | 1 |
| Delion, P | 1 |
| Jardri, R | 1 |
| Mittoux, A | 1 |
| He, Y | 1 |
| Peuskens, J | 1 |
| Liou, YJ | 2 |
| Bai, YM | 2 |
| Lin, E | 1 |
| Chen, JY | 1 |
| Chen, TT | 2 |
| Hong, CJ | 2 |
| Tsai, SJ | 2 |
| Cerit, C | 1 |
| Vural, M | 1 |
| Bos Gelmez, SÜ | 1 |
| Ozten, E | 1 |
| Aker, AT | 1 |
| Yıldız, M | 1 |
| Lee, NY | 1 |
| Kim, SH | 1 |
| Jung, DC | 1 |
| Kim, EY | 1 |
| Yu, HY | 1 |
| Sung, KH | 1 |
| Kang, UG | 1 |
| Ahn, YM | 1 |
| Kim, YS | 1 |
| Tsai, MC | 1 |
| Chang, CM | 1 |
| Liu, CY | 1 |
| Chang, PY | 1 |
| Huang, TL | 1 |
| Xie, D | 1 |
| Fiedorowicz, JG | 1 |
| Haynes, WG | 1 |
| Kaushal, J | 1 |
| Bhutani, G | 1 |
| Gupta, R | 1 |
| Jin, H | 1 |
| Shih, PA | 1 |
| Golshan, S | 1 |
| Mudaliar, S | 1 |
| Henry, R | 1 |
| Glorioso, DK | 1 |
| Arndt, S | 1 |
| Kraemer, HC | 1 |
| Jeste, DV | 1 |
| Mosolov, SN | 1 |
| Kabanov, SO | 1 |
| Alméras, N | 1 |
| Després, JP | 1 |
| Villeneuve, J | 1 |
| Demers, MF | 1 |
| Roy, MA | 1 |
| Cadrin, C | 1 |
| Mottard, JP | 1 |
| Bouchard, RH | 1 |
| Henderson, DC | 2 |
| Cagliero, E | 1 |
| Copeland, PM | 2 |
| Borba, CP | 2 |
| Evins, AE | 2 |
| Hayden, D | 1 |
| Weber, MT | 1 |
| Anderson, EJ | 1 |
| Allison, DB | 1 |
| Daley, TB | 1 |
| Schoenfeld, D | 1 |
| Goff, DC | 2 |
| Karagianis, JL | 1 |
| Dunayevich, E | 1 |
| Nguyen, DD | 1 |
| Hayden, DL | 1 |
| Louie, PM | 1 |
| Freudenreich, O | 1 |
| Cather, C | 1 |
| McKee, JR | 1 |
| Bodfish, JW | 1 |
| Mahorney, SL | 1 |
| Heeth, WL | 1 |
| Ball, MP | 1 |
| Birkás Kováts, D | 1 |
| Palik, E | 1 |
| Faludi, G | 1 |
| Cseh, K | 1 |
| Meyer, JM | 1 |
| Pandina, G | 1 |
| Bossie, CA | 1 |
| Turkoz, I | 1 |
| Greenspan, A | 1 |
| Wu, RR | 1 |
| Zhao, JP | 1 |
| Liu, ZN | 1 |
| Zhai, JG | 1 |
| Guo, XF | 1 |
| Guo, WB | 1 |
| Tang, JS | 1 |
| Yumru, M | 1 |
| Savas, HA | 1 |
| Kurt, E | 1 |
| Kaya, MC | 1 |
| Selek, S | 1 |
| Savas, E | 1 |
| Oral, ET | 1 |
| Atagun, I | 1 |
| Saddichha, S | 1 |
| Ameen, S | 2 |
| Akhtar, S | 2 |
| Sahoo, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Long-Term Safety, Tolerability, and Effectiveness of Lurasidone in Subjects With Schizophrenia or Schizoaffective Disorder: A Randomized, Active Comparator-Controlled Trial[NCT00641745] | Phase 3 | 629 participants (Actual) | Interventional | 2008-03-31 | Completed | ||
| Monitoring of Metabolic Adverse Events of Second Generation Antipsychotics in a Naive Pediatric Population Followed in Mental Health Outpatient and Inpatient Clinical Settings (MEMAS Prospective Study)[NCT04395326] | 120 participants (Anticipated) | Observational | 2017-01-01 | Recruiting | |||
| Risperidone and Behavioral Therapy in Treatment of Children and Adolescents With Autistic Disorder[NCT00080145] | 124 participants (Actual) | Interventional | 2004-02-29 | Completed | |||
| Sertindole Versus Risperidone Safety Outcome Study: a Randomised, Partially-blinded, Parallel-group, Active-controlled, Post-marketing Study[NCT00856583] | Phase 3 | 9,809 participants (Actual) | Interventional | 2002-07-31 | Completed | ||
| Metabolic Effects of Newer Antipsychotics in Older Patients[NCT00245206] | Phase 4 | 406 participants (Actual) | Interventional | 2005-08-31 | Completed | ||
| Phase IV Study of Ramelteon as an Adjunct Therapy in Non-Diabetic Patients With Schizophrenia[NCT00595504] | Phase 4 | 25 participants (Actual) | Interventional | 2008-01-31 | Completed | ||
| Phase 4 Study of the Effects of Pravastatin on Cholesterol Levels, Inflammation and Cognition in Schizophrenia[NCT01082588] | Phase 4 | 60 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00641745)
Timeframe: 12 months
| Intervention | participants (Number) |
|---|---|
| Lurasidone | 395 |
| Risperidone | 189 |
"The analysis was based on all deaths from the WRT+30 days period using the classification performed by the ISC.~The ISC reviewed and classified those adverse events which resulted in death or hospitalisation or were possible suicide attempts and this review was blinded to exposure. The definition of cardiac death was intentionally wide; sudden or unexplained deaths were assumed to be cardiac if there was no non-cardiac explanation. To ensure consistent evaluation and classification, the ISC decided a priori to classify all instances of self harm as possible suicide." (NCT00856583)
Timeframe: As study design allowed patients to continue study drug until the study was closed, many patients were followed for several years, with an overall median time period of approximately 14 months
| Intervention | participants (Number) |
|---|---|
| Sertindole | 31 |
| Risperidone | 12 |
The analysis was based on all deaths from the WRT+30 days period using the classification based upon the Medical Dictionary for Regulatory Activities (MedDRA) terminology, that is, as reported by the investigator (NCT00856583)
Timeframe: As study design allowed patients to continue study drug until the study was closed, many patients were followed for several years, with an overall median time period of approximately 14 months
| Intervention | participants (Number) |
|---|---|
| Sertindole | 17 |
| Risperidone | 8 |
"The analysis was based on all deaths from the WRT+30 days period using the classification performed by the ISC.~The ISC reviewed and classified those adverse events which resulted in death or hospitalisation or were possible suicide attempts and this review was blinded to exposure. The definition of cardiac death was intentionally wide; sudden or unexplained deaths were assumed to be cardiac if there was no non-cardiac explanation. To ensure consistent evaluation and classification, the ISC decided a priori to classify all instances of self harm as possible suicide." (NCT00856583)
Timeframe: As study design allowed patients to continue study drug until the study was closed, many patients were followed for several years, with an overall median time period of approximately 14 months
| Intervention | participants (Number) |
|---|---|
| Sertindole | 14 |
| Risperidone | 21 |
The analysis was based on all deaths from the WRT+30 days period using the classification based upon MedDRA terminology, that is, as reported by the investigator (NCT00856583)
Timeframe: As study design allowed patients to continue study drug until the study was closed, many patients were followed for several years, with an overall median time period of approximately 14 months
| Intervention | participants (Number) |
|---|---|
| Sertindole | 13 |
| Risperidone | 21 |
"The analysis was based on all deaths from the WRT+30 days period using the classification performed by the ISC.~The ISC reviewed and classified those adverse events which resulted in death or hospitalisation or were possible suicide attempts and this review was blinded to exposure. The definition of cardiac death was intentionally wide; sudden or unexplained deaths were assumed to be cardiac if there was no non-cardiac explanation. To ensure consistent evaluation and classification, the ISC decided a priori to classify all instances of self harm as possible suicide." (NCT00856583)
Timeframe: As study design allowed patients to continue study drug until the study was closed, many patients were followed for several years, with an overall median time period of approximately 14 months
| Intervention | participants (Number) |
|---|---|
| Sertindole | 19 |
| Risperidone | 28 |
The analysis was based on all deaths from the WRT+30 days period using the classification based upon MedDRA terminology, that is, as reported by the investigator (NCT00856583)
Timeframe: As study design allowed patients to continue study drug until the study was closed, many patients were followed for several years, with an overall median time period of approximately 14 months
| Intervention | participants (Number) |
|---|---|
| Sertindole | 34 |
| Risperidone | 32 |
The analysis was based on time from start of study drug until stop of study drug for any reason other than sponsor closure of the study (NCT00856583)
Timeframe: As study design allowed patients to continue study drug until the study was closed, many patients were followed for several years, with an overall median time period of approximately 14 months
| Intervention | participants (Number) |
|---|---|
| Sertindole | 3136 |
| Risperidone | 2597 |
The analysis was based on time from start of study drug to first hospitalisation during the WRT+30 days period (NCT00856583)
Timeframe: As study design allowed patients to continue study drug until the study was closed, many patients were followed for several years, with an overall median time period of approximately 14 months
| Intervention | participants (Number) |
|---|---|
| Sertindole | 174 |
| Risperidone | 149 |
"The analysis was based on all suicides and suicide attempts from the WRT+30 days period using the classification performed by the ISC.~The ISC reviewed and classified those adverse events which resulted in death or hospitalisation or were possible suicide attempts and this review was blinded to exposure. The definition of cardiac death was intentionally wide; sudden or unexplained deaths were assumed to be cardiac if there was no non-cardiac explanation. To ensure consistent evaluation and classification, the ISC decided a priori to classify all instances of self harm as possible suicide." (NCT00856583)
Timeframe: As study design allowed patients to continue study drug until the study was closed, many patients were followed for several years, with an overall median time period of approximately 14 months
| Intervention | participants (Number) |
|---|---|
| Sertindole | 68 |
| Risperidone | 76 |
The analysis was based on all suicides and suicide attempts from the WRT+30 days period using the classification based upon MedDRA terminology, that is, as reported by the investigator (NCT00856583)
Timeframe: As study design allowed patients to continue study drug until the study was closed, many patients were followed for several years, with an overall median time period of approximately 14 months
| Intervention | participants (Number) |
|---|---|
| Sertindole | 43 |
| Risperidone | 65 |
Second primary endpoint: a serious adverse event where the patient was hospitalised and for which the Independent Safety Committee (ISC) classified the event as a cardiac event with documented arrhythmia. The analysis of this outcome was not performed due to low number of events. The presented analysis is a replacement analysis using all cardiac events, including arrhythmias, that required hospitalisation (NCT00856583)
Timeframe: As study design allowed patients to continue study drug until the study was closed, many patients were followed for several years, with an overall median time period of approximately 14 months
| Intervention | participants (Number) |
|---|---|
| Sertindole | 10 |
| Risperidone | 6 |
The analysis was based on all deaths from the Whole Randomised Treatment (WRT)+30 days period and the Only Randomised Treatment (ORT) period, respectively (NCT00856583)
Timeframe: As study design allowed patients to continue study drug until the study was closed, many patients were followed for several years, with an overall median time period of approximately 14 months
| Intervention | participants (Number) | |
|---|---|---|
| Number of deaths (WRT+30 days) | Number of deaths (ORT) | |
| Risperidone | 61 | 44 |
| Sertindole | 64 | 40 |
A comparison between the ramelteon group and the placebo group of change in abdominal fat measured by a DEXA scan, assessed at Baseline and Week 8. (NCT00595504)
Timeframe: Baseline and Week 8
| Intervention | g (Mean) |
|---|---|
| Ramelteon | 3934.86 |
| Placebo (Sugar Pill) | 5120.92 |
A comparison between the ramelteon group and the placebo group of change in insulin resistance measured by the homeostatic model assessment of insulin resistance (HOMA-IR), assessed at Baseline and Week 8. (NCT00595504)
Timeframe: Baseline and Week 8
| Intervention | HOMA score (Mean) |
|---|---|
| Ramelteon | 2.4 |
| Placebo (Sugar Pill) | 2.36 |
A comparison between the ramelteon group and the placebo group in change in waist circumference (measured in cm) measured at Baseline and Week 8. (NCT00595504)
Timeframe: Baseline and Week 8
| Intervention | cm (Mean) |
|---|---|
| Ramelteon | 106.09 |
| Placebo (Sugar Pill) | 108.37 |
(NCT01082588)
Timeframe: Baseline, week 12
| Intervention | mg/L (Mean) |
|---|---|
| Pravastatin | 0.8063 |
| Placebo | -0.5136 |
(NCT01082588)
Timeframe: Baseline, week 12
| Intervention | mg/dl (Mean) |
|---|---|
| Pravastatin | -25.565 |
| Placebo | -2.913 |
"The Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery measures cognitive functioning within 7 domains: speed of processing, attention/vigilance, working memory (non verbal and verbal), verbal learning, visual learning, reasoning and problem solving and social cognition.~The composite score is calculated by the MATRICS computer program, which equally weights each of the 7 domain scores. The range of composite scores is 20-80. Higher scores indicate higher levels or cognitive functioning, while lower scores indicate lower levels of cognitive functioning." (NCT01082588)
Timeframe: Baseline, week 12
| Intervention | Scores on a scale (Mean) |
|---|---|
| Pravastatin | 4.0417 |
| Placebo | 4.125 |
This is a subscale of the Positive and Negative Syndrome Scale (PANSS). The range for this subscale is 15-105. All items are summed to calculate the total score. Better outcomes have lower numbers and worse outcomes have higher numbers. (NCT01082588)
Timeframe: Baseline, week 12
| Intervention | Scores on a scale (Mean) |
|---|---|
| Pravastatin | -5.625 |
| Placebo | -3.76 |
This is a subscale of the Positive and Negative Syndrome Scale (PANSS). The range for this subscale is 7-49. All items are summed to calculate the total score. Better outcomes have lower numbers and worse outcomes have higher numbers. (NCT01082588)
Timeframe: Baseline, week 12
| Intervention | Scores on a scale (Mean) |
|---|---|
| Pravastatin | -0.83 |
| Placebo | -0.28 |
This is a subscale of the Positive and Negative Syndrome Scale (PANSS). The range for this subscale is 7-49. All items are summed to calculate the total score. Better outcomes have lower numbers and worse outcomes have higher numbers. (NCT01082588)
Timeframe: Baseline, week 12
| Intervention | Scores on a scale (Mean) |
|---|---|
| Pravastatin | -2.9583 |
| Placebo | -2.44 |
The Positive and Negative Syndrome Scale (PANSS) is a scale used to rate severity of schizophrenia. All items are summed to calculate the total score. The scale range is 30-210. Better outcomes have lower numbers and worse outcomes have higher numbers. (NCT01082588)
Timeframe: Baseline, week 12
| Intervention | Scores on a scale (Mean) |
|---|---|
| Pravastatin | -9.416 |
| Placebo | -6.48 |
5 reviews available for risperidone and Metabolic Syndrome
| Article | Year |
|---|---|
HTR2C polymorphisms, olanzapine-induced weight gain and antipsychotic-induced metabolic syndrome in schizophrenia patients: a meta-analysis.
Topics: Alleles; Antipsychotic Agents; Benzodiazepines; Clozapine; Female; Genetic Association Studies; Huma | 2014 |
Behavioral Disorders in Dementia: Appropriate Nondrug Interventions and Antipsychotic Use.
Topics: Antipsychotic Agents; Aripiprazole; Arrhythmias, Cardiac; Basal Ganglia Diseases; Behavior Therapy; | 2016 |
HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia: a replication study.
Topics: Adult; Antipsychotic Agents; Clozapine; Cross-Sectional Studies; Female; Humans; Linkage Disequilibr | 2009 |
Are weight gain and metabolic side effects of atypical antipsychotics dose dependent? A literature review.
Topics: Adolescent; Adult; Antipsychotic Agents; Child; Clozapine; Controlled Clinical Trials as Topic; Dose | 2009 |
[The appearance of metabolic syndrome in treatment with atypical antipsychotics].
Topics: Adolescent; Adult; Age Factors; Aged; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Body W | 2003 |
12 trials available for risperidone and Metabolic Syndrome
| Article | Year |
|---|---|
Efficacy and safety of electroacupuncture on metabolic syndrome due to olanzapine and risperidone: Study protocol for a randomized controlled pilot trial.
Topics: Antipsychotic Agents; Clinical Protocols; Electroacupuncture; Humans; Metabolic Syndrome; Olanzapine | 2019 |
Metabolic Effects of 7 Antipsychotics on Patients With Schizophrenia: A Short-Term, Randomized, Open-Label, Multicenter, Pharmacologic Trial.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Female | 2020 |
Switching to Lurasidone following 12 months of treatment with Risperidone: results of a 6-month, open-label study.
Topics: Adult; Antipsychotic Agents; Double-Blind Method; Female; Humans; Lurasidone Hydrochloride; Male; Me | 2020 |
Effects of switching from olanzapine, quetiapine, and risperidone to aripiprazole on 10-year coronary heart disease risk and metabolic syndrome status: results from a randomized controlled trial.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Coronary Artery Disease; Dibenzothiazepi | 2013 |
Weight Gain and Metabolic Consequences of Risperidone in Young Children With Autism Spectrum Disorder.
Topics: Antipsychotic Agents; Autism Spectrum Disorder; Child; Child, Preschool; Female; Humans; Insulin Res | 2016 |
Mifepristone reduces weight gain and improves metabolic abnormalities associated with risperidone treatment in normal men.
Topics: Adolescent; Adult; Analysis of Variance; Antipsychotic Agents; Double-Blind Method; Hormone Antagoni | 2010 |
A head-to-head comparison of sertindole and risperidone on metabolic parameters.
Topics: Adult; Antipsychotic Agents; Body Mass Index; Cholesterol; Female; Humans; Imidazoles; Indoles; Lipi | 2010 |
Comparison of fasting blood sugar and serum lipid profile changes after treatment with atypical antipsychotics olanzapine and risperidone.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Cholesterol; Female; Humans | 2012 |
Comparison of longer-term safety and effectiveness of 4 atypical antipsychotics in patients over age 40: a trial using equipoise-stratified randomization.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bi | 2013 |
Effects of switching from olanzapine to risperidone on the prevalence of the metabolic syndrome in overweight or obese patients with schizophrenia or schizoaffective disorder: analysis of a multicenter, rater-blinded, open-label study.
Topics: Adult; Antipsychotic Agents; Behavior Therapy; Benzodiazepines; Blood Pressure; Body Mass Index; Bod | 2005 |
Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Mass Index; C-Peptide; Cholesterol | 2006 |
Incidence of new onset metabolic syndrome with atypical antipsychotics in first episode schizophrenia: a six-week prospective study in Indian female patients.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Female; Humans; Incidence; India; | 2007 |
28 other studies available for risperidone and Metabolic Syndrome
| Article | Year |
|---|---|
The atypical antipsychotic risperidone targets hypothalamic melanocortin 4 receptors to cause weight gain.
Topics: alpha-MSH; Animals; Antipsychotic Agents; Female; Hyperphagia; Hypothalamus; Male; Metabolic Syndrom | 2021 |
Metabolic changes in first-episode early-onset schizophrenia with second-generation antipsychotics.
Topics: Adolescent; Age of Onset; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Cholesterol; Diben | 2014 |
Effects of vitamin D receptor polymorphisms on the risk of schizophrenia and metabolic changes caused by risperidone treatment.
Topics: Adolescent; Adult; Antipsychotic Agents; Asian People; Case-Control Studies; China; Female; Humans; | 2014 |
Cardiometabolic outcomes in children and adolescents following discontinuation of long-term risperidone treatment.
Topics: Adolescent; Cardiovascular Diseases; Child; Female; Follow-Up Studies; Humans; Male; Metabolic Syndr | 2014 |
Effects of second-generation antipsychotics on selected markers of one-carbon metabolism and metabolic syndrome components in first-episode schizophrenia patients.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Mass Index; Carbon; Cholesterol; F | 2014 |
Increased Risk of Obesity and Metabolic Dysregulation Following 12 Months of Second-Generation Antipsychotic Treatment in Children: A Prospective Cohort Study.
Topics: Adolescent; Antipsychotic Agents; Anxiety Disorders; Attention Deficit and Disruptive Behavior Disor | 2015 |
Association between SCAP and SREBF1 gene polymorphisms and metabolic syndrome in schizophrenia patients treated with atypical antipsychotics.
Topics: Adult; Alleles; Antipsychotic Agents; Benzodiazepines; Case-Control Studies; China; Clozapine; Femal | 2016 |
Metformin-Induced Type 1 Hypersensitivity in a Child with Antipsychotic-Induced Weight Gain.
Topics: Antipsychotic Agents; Bipolar Disorder; Child; Drug Hypersensitivity; Humans; Hypersensitivity, Imme | 2017 |
Second-Generation Antipsychotic Utilization and Metabolic Parameter Monitoring in an Inpatient Pediatric Population: A Retrospective Analysis.
Topics: Adolescent; Antipsychotic Agents; Child; Child, Preschool; Female; Humans; Inpatients; Male; Metabol | 2017 |
Atypical antipsychotics and metabolic outcomes in Chinese patients: a comparison of olanzapine and risperidone.
Topics: Adult; Aged; Antipsychotic Agents; Benzodiazepines; China; Cross-Sectional Studies; Dose-Response Re | 2008 |
Weight gain and metabolic abnormalities during extended risperidone treatment in children and adolescents.
Topics: Adolescent; Antipsychotic Agents; Body Mass Index; Child; Cholesterol, HDL; Drug Administration Sche | 2009 |
Effects of olanzapine and risperidone on metabolic factors in children and adolescents: a retrospective evaluation.
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Child; Diabetes Mellitus, Type 2 | 2009 |
A naturalistic study of predictors and risks of atypical antipsychotic use in an attention-deficit/hyperactivity disorder clinic.
Topics: Adolescent; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Central Nervous Sys | 2009 |
[Metabolic side effects of risperidone in early onset schizophrenia].
Topics: Adolescent; Age Factors; Antipsychotic Agents; Body Mass Index; Child; Female; Humans; Hypercholeste | 2010 |
Gene-gene interactions of the INSIG1 and INSIG2 in metabolic syndrome in schizophrenic patients treated with atypical antipsychotics.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Case-Control Studies; Cross-Sectional Studies; Epistas | 2012 |
Association between HTR2C polymorphisms and metabolic syndrome in patients with schizophrenia treated with atypical antipsychotics.
Topics: Adult; Alleles; Antipsychotic Agents; Benzodiazepines; Clozapine; Female; Gene Frequency; Genetic Li | 2011 |
Metabolic syndrome with different antipsychotics: a multicentre cross-sectional study.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Chi-Square Distribution; Clopenthixo | 2010 |
The prevalence of metabolic syndrome in Korean patients with schizophrenia receiving a monotherapy with aripiprazole, olanzapine or risperidone.
Topics: Adult; Age Factors; Antipsychotic Agents; Aripiprazole; Asian People; Benzodiazepines; Cohort Studie | 2011 |
Association of serum levels of leptin, ghrelin, and adiponectin in schizophrenic patients and healthy controls.
Topics: Adiponectin; Adult; Antipsychotic Agents; Case-Control Studies; Clozapine; Female; Ghrelin; Humans; | 2011 |
Rate of weight gain and cardiometabolic abnormalities in children and adolescents.
Topics: Adolescent; Antipsychotic Agents; Biomarkers; Blood Pressure; Body Mass Index; Child; Female; Humans | 2012 |
Development of an atherogenic metabolic risk factor profile associated with the use of atypical antipsychotics.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Biomarkers; Carrier State; Cholesterol, HDL; Coronary | 2004 |
Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Mass Index; Body Weight; Clozapine | 2005 |
Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Mass Index; Body Weight; Clozapine | 2005 |
Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Mass Index; Body Weight; Clozapine | 2005 |
Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Mass Index; Body Weight; Clozapine | 2005 |
Development of an atherogenic metabolic risk factor profile associated with the use of atypical antipsychotics.
Topics: Antipsychotic Agents; Benzodiazepines; Bias; Biomarkers; Coronary Artery Disease; Cross-Sectional St | 2005 |
Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study.
Topics: Adult; Antipsychotic Agents; Black or African American; Cardiovascular Diseases; Cause of Death; Clo | 2005 |
Metabolic effects associated with atypical antipsychotic treatment in the developmentally disabled.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Mass Index; Cholesterol; Comorbidi | 2005 |
[Possible connection between ghrelin, resistin and TNF-alpha levels and the metabolic syndrome caused by atypical antipsychotics].
Topics: Antipsychotic Agents; Benzodiazepines; Carbohydrate Metabolism; Case-Control Studies; Clozapine; Dib | 2005 |
Atypical antipsychotics related metabolic syndrome in bipolar patients.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Body Mass Index; Carbama | 2007 |
Metabolic syndrome in drug-naïve first-episode psychosis treated with atypical antipsychotics.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Blood Pressure; Cross-Sectional Studies; Dibenzothiaze | 2007 |